www.fdanews.com/articles/179494-helsinn-integrative-care-gains-fda-clearance-for-xonrid-gel
Helsinn Integrative Care Gains FDA Clearance for Xonrid Gel
December 1, 2016
Helsinn Integrative Care has received FDA marketing clearance for Xonrid gel which is used for radiotherapy-induced dermatitis.
It is recognized in the EU as a medical device, so the FDA acknowledges it as a device too.
The product is intended to be used for less than 30 days and not on open wounds. — Cynthia Jessup